Eric Olson - Syros Pharmaceuticals Chief Scientific Officer
| SYRS Stock | USD 0.27 0.02 8.00% |
Executive
Mr. Eric R. Olson Ph.D. is Chief Scientific Officer of the Company. He previously served as research vice president for respiratory diseases at Vertex Pharmaceuticals, Inc., a biotechnology company, from 2001 to May 2013. Dr. Olson has also held positions as the director of antibacterials and molecular sciences departments at WarnerLambert Co. as well as a research scientist focused on gene expression systems with The Upjohn Company, both of which were acquired by Pfizer Inc., a pharmaceutical company since 2013.
| Age | 66 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 35 CambridgePark Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 744 1340 |
| Web | https://www.syros.com |
Syros Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.27 in 2024, whereas Total Assets are likely to drop slightly above 147.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christopher Dinsmore | Kronos Bio | 57 | |
| Mick OQuigley | Ideaya Biosciences | N/A | |
| Zung To | Kezar Life Sciences | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Li Yang | Surrozen | 55 | |
| Kirk RAC | Xencor Inc | 59 | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| MPH DO | Kronos Bio | 59 | |
| Margaux Bennett | Kronos Bio | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Nancy MD | Xencor Inc | 65 | |
| Stu Dorman | Ideaya Biosciences | N/A | |
| Dane CFA | Xencor Inc | N/A | |
| Joe Tedrick | Kezar Life Sciences | N/A | |
| Allison JD | Kronos Bio | 41 | |
| Karl Whitney | Passage Bio | N/A | |
| Stuart Henderson | Passage Bio | N/A | |
Management Performance
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 |
Syros Pharmaceuticals Leadership Team
Elected by the shareholders, the Syros Pharmaceuticals' board of directors comprises two types of representatives: Syros Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syros. The board's role is to monitor Syros Pharmaceuticals' management team and ensure that shareholders' interests are well served. Syros Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syros Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James MD, Founder | ||
| Lisa Roberts, Vice Resources | ||
| Christian Fritz, Vice President - Biology | ||
| JD Esq, Chief Development | ||
| Conley Chee, President CEO | ||
| Eric Olson, Chief Scientific Officer | ||
| Jason Haas, Chief Officer | ||
| Courtney Solberg, Mang Relations | ||
| Kristin Stephens, Chief Officer | ||
| Nancy MD, CEO Pres | ||
| Richard Young, Independent Director | ||
| Nathanael Gray, Scientific Board | ||
| David MD, Chief Officer | ||
| Karen MS, Director Relations |
Syros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syros Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (288.92) % | ||||
| Current Valuation | 9.13 M | ||||
| Shares Outstanding | 26.83 M | ||||
| Shares Owned By Insiders | 1.37 % | ||||
| Shares Owned By Institutions | 75.58 % | ||||
| Number Of Shares Shorted | 4.77 M | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 10.65 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.